Neurobiology of Aging
Volume 27, Issue 10 , Pages 1431-1434 , October 2006

Genetic variability at the LXR gene (NR1H2) may contribute to the risk of Alzheimer's disease

Received 30 June 2005 ,Revised 3 August 2005 ,Accepted 26 August 2005.

References 

  1. Alberti S, Schuster G, Parini P, Feltkamp D, Diczfalusy U, Rudling M, et al. Hepatic cholesterol metabolism and resistance to dietary cholesterol in LXRbeta-deficient mice. J Clin Invest. 2001;107:565–573
  2. Bertram L, Tanzi RE. Alzheimer's disease: one disorder, too many genes?. Hum Mol Genet. 2004;13(Spec No 1):R135–R141
  3. Blacker D, Bertram L, Saunders AJ, Moscarillo TJ, Albert MS, Wiener H, et al. NIMH Genetics Initiative Alzheimer's Disease Study Group Results of a high-resolution genome screen of 437 Alzheimer's disease families. Hum Mol Genet. 2003;12(1):23–32
  4. Brown J, Theisler C, Silberman S, Magnuson D, Gottardi-Littell N, Lee JM, et al. Differential expression of cholesterol hydroxylases in Alzheimer's disease. J Biol Chem. 2004;379:34674–34681
  5. Compton D, Wavrant DeVrieze F, Petersen RC, Tangalos E, Li L, Hardy J. Possible association between genetic variability at the apolipoprotein(a) locus and Alzheimer's disease in apolipoprotein E2 carriers. Neurosci Lett. 2002;331(1):60–62
  6. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261(5123):921–923
  7. Fukuchi J, Song C, Ko AL, Liao S. Transcriptional regulation of farnesyl pyrophosphate synthase by liver X receptors. Steroids. 2003;68:685–691
  8. Fukumoto H, Deng A, Irizarry M, Fitzgeralds M, Rebeck W. Induction of cholesterol transporter ABCA1 in central nervous system cells by liver X receptor agonist increases secreted Aβ levels. J Biol Chem. 2002;277(50):48508–48513
  9. Jarvik GP, Wijsman EM, Kukull WA, Schellenberg GD, Yu C, Larson EB. Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease: a case–control study. Neurology. 1995;45(6):1092–1096
  10. Kehoe P, Wavrant-De Vrièze F, Crook R, Wu WS, Holmans P, Fenton L, et al. A full genome scan for late onset Alzheimer's disease. Hum Mol Genet. 1999;8:237–245
  11. Koldamova RP, Lefterov IM, Staufenbiel M, Wolfe D, Huang S, Glorioso JC, et al. The liver X receptor ligand T0901317 decreases amyloid beta production in vitro and in a mouse model of Alzheimer's disease. J Biol Chem. 2005;280(6):4079–4088
  12. Koldamova RP, Lefterov IM, Ikonomovic MD, Skoko J, Lefterov PI, Isanski BA, et al. 22R-hydroxycholesterol and 9-cis-retinoic acid induce ATP-binding cassette transporter A1 expression and cholesterol efflux in brain cells and decrease amyloid beta secretion. J Biol Chem. 2003;278:13244–13256
  13. Li Y, Tacey K, Doil L, van Luchene R, Garcia V, Rowland C, et al. Association of ABCA1 with late-onset Alzheimer's disease is not observed in a case–control study. Neurosci Lett. 2004;366(3):268–271
  14. Liang Y, Lin S, Beyer TP, Zhang Y, Wu X, Bales KR, et al. A liver X receptor and retinoid X receptor heterodimer mediates apolipoprotein E expression, secretion and cholesterol homeostasis in astrocytes. J Lipid Res. 2002;43(12):2037–2041
  15. Murthy S, Born E, Mathur SN, Field J. LXR/RXR activation enhances basolateral efflux of cholesterol in CaCo-2 cells. J Lipid Res. 2002;43:1054–1064
  16. Myers A, Wavrant De-Vrieze F, Holmans P, Hamshere M, Crook R, Compton D, et al. Full genome screen for Alzheimer disease: stage II analysis. Am J Med Genet (Neuropsychiatric Genet). 2002;114:235–244
  17. Notkola IL, Sulkava R, Pekkanen J, Erkinjuntti T, Ehnholm C, Kivinen P, et al. Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease. Neuroepidemiology. 1998;17(1):14–20
  18. Pittman AM, Myers AJ, Duckworth J, Bryden L, Hanson M, Abou-Sleiman P, et al. The structure of tau haplotype in controls and in progressive supranuclear palsy. Hum Mol Genet. 2004;13:1267–1274
  19. Poirier J. Apolipoprotein E, cholesterol transport and synthesis in sporadic Alzheimer's disease. Neurobiol Aging. 2005;26(3):355–361
  20. Refolo LM, Pappolla MA, LaFrancois J, Malester B, Schmidt SD, Thomas-Bryant T, et al. A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol Dis. 2001;8(5):890–899
  21. Sun Y, Yao J, Kim TW, Tall AR. Expression of liver X receptor target genes decreases cellular amyloid beta peptide secretion. J Biol Chem. 2003;278:27688–27694
  22. Wijsman EM, Daw EW, Yu C, Payami H, Steinbart EJ, Nochlin D, et al. Evidence for a novel late-onset Alzheimer's disease locus on chromosome 19p13.2. Am J Hum Genet. 2004;75:398–409
  23. Wolozin B. Cholesterol and biology of Alzheimer's disease. Neuron. 2004;41:7–10

PII: S0197-4580(05)00239-3

doi: 10.1016/j.neurobiolaging.2005.08.010

Neurobiology of Aging
Volume 27, Issue 10 , Pages 1431-1434 , October 2006

Article Tools